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Abstract 
Review on TRIM27, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: RFP, RNF76 
HGNC (Hugo): TRIM27 
Location: 6p22.1 
DNA/RNA 
Description 
The unprocessed TRIM27 transcript spans 20.990 
kb and is organised in 8 exons.  
Reporter construct studies suggest the presence of 
elements between -365 and -68 relative to the 
transcription start point to be sufficient to drive 
basal gene transcription.  
This promoter region is GC rich and has no typical 
TATA and CAAT boxes (Iwata et al., 1999). 
Transcription 
Alternative splicing of the human locus may 
generate 7 or more processed alternative transcripts. 
Three of these transcripts contain open reading 
frames and presumably give rise to protein products 
(Ensembl). 
Transcript 1: 2969 bps (transcript ID 
ENST00000377199, protein encoding, protein ID 
ENSP00000366404); 
Transcript 2: 2704 bps (transcript ID 
ENST00000377194, protein encoding, protein ID  
 
ENSP00000366399); 
Transcript 3: 1813 bps (transcript ID 
ENST00000414543, protein encoding, protein ID 
ENSP00000400058); 
Transcript 4: 7006 bps (transcript ID 
ENST00000481474, processed transcript without 
open reading frame); 
Transcript 5: 687 bps (transcript ID 
ENST00000496091, processed transcript without 
open reading frame); 
Transcript 6: 541 bps (transcript ID 
ENST00000467742, processed transcripts without 
open reading frame); 
Transcript 7: 7006 bps (transcript ID 
ENST00000481474, retains intronic sequence 
relative to other coding transcripts, without open 
reading frame). 
Pseudogene 
There are no reported pseudogenes of TRIM27. 
Protein 
Description 
The longest isoform 1 of TRIM27 (protein ID 
ENSP00000366404) encodes a 513 amino acids 
protein with a molecular weight of 58 KDa; 
displaying the so-called tripartite/RBCC motif 
within its N-terminal region, composed of a RING 
type zinc finger (InterPro ID IPR001841) (aa 16-
57), a B-box type zinc finger (InterPro ID001841) 
(aa 96-127) and coiled-coil domains (aa 132-172 
and aa 282-311), and a B30.2/PRY-SPRY domain 
(InterPro ID IPR001870) within its C-terminal 
region (aa 298-492). 
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Schematic diagram of TRIM27 protein. The domain structure of the three TRIM27 protein isoforms (i-iii) and a ribbon diagram 
of the structure of TRIM27 domains which represents a high confidence model generated by Phyre2 
(http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index). NH2, Amino-terminal region; COOH, Carboxyl-terminal region. 
 
The RING finger may be involved in mediating 
protein-protein interactions and may confer 
ubiquitin family ligase activity. TRIM27 can form 
homo and hetero-oligomeric assemblies mediated 
by the centrally located coiled-coil domain (Cao et 
al., 1997). Isoform 2 (protein ID 
ENSP00000366399) lacks the C-terminal SPRY 
domain. Isoform 3 (protein ID ENSP00000400058) 
encodes the B30.2/PRY-SPRY domain only. The 
diagram above is a scheme of the protein isoforms 
and their domains. 
Expression 
TRIM27 transcripts and protein is ubiquitous in day 
10.5-13.5 mouse embryos. Expression is restricted 
in adult mice, with the highest level of expression 
in pachytene spermatocytes and round spermatids 
of differentiating sperm (Cao et al., 1996; Tezel et 
al., 1999). TRIM27 is also expressed in mouse 
spleen, thymus, cerebrum and cerebellum. TRIM27 
is expressed in various human and rodent cell lines. 
Based on RNAseq., TRIM27 mRNA is detected 
widely in human tissues, with no evidence for 
absence. Expression levels between tissues are 
similar, including testes, with comparative 
expression rating of low to medium across tissues 
(Human Protein Atlas). 
Localisation 
The protein localizes to the nucleus, cytoplasm and 
in nuclear bodies (NB) associated with the nuclear 
matrix (Isomura et al., 1992). Nuclear export of 
RFP is dependent on a functional NES, which can 
be activated by protein kinase C (PKC) (Harbers et 
al., 2001). Hetero-oligomerization has been 
observed between TRIM27 and TRIM19 with the 
recruitment of TRIM27 to the promyelocytic 
leukaemia nuclear bodies (PMLs) (Cao et al., 
1998). Furthermore, interaction with members of 
the protein inhibitors of activated STAT (PIAS) 
family targets TRIM27 to subnuclear 
compartments/NBs, involving TRIM27 
sumoylation (Matsuura et al., 2005). Nuclear or 
cytoplasmic localisation depends on the cell type or 
tissue. 
Function 
A role for TRIM27 has been reported in 
transcriptional regulation through interaction with 
retinoblastoma protein (RB1) and the Mi-2b-
containing histone deacetylase complex in the 
nucleus (Krutzfeldt et al., 2005; Shimono et al., 
2005), in transcriptional repression through 
interaction with the enhancer of polycomb protein 
(EPC) (Shimono et al., 2000; Bloor et al., 2005) 
and MBD proteins (Fukushige et al., 2006), in the 
negative regulation of NF-kB and IFN-signaling 
pathways (Zha et al., 2006), in the positive 
regulation of apoptosis through activation of Jun N-
terminal kinase (JNK) (Dho and Kwon, 2003) and 
augmentation of TNF alpha receptor activation 
(Zaman et al., 2013), and in cell cycle regulation 
(Patel and Ghiselli, 2005) suggesting that TRIM27 
is involved in the control of multiple cellular 
processes. TRIM27 has been shown to confer E3 
ubiquitin ligase activity with the enzymes UBE2D1 
and UBE2D3 (Napolitano et al., 2011) and to 
possess SUMO E3 ligase activity (Chu and Yang, 
2011). TRIM27 regulates innate immune responses 
by physical interaction with NOD2. So, TRIM27 
mediates K48-linked ubiquitination and subsequent 
proteasomal degradation of NOD2 (Zurek et al., 
2012). TRIM27 has a critical role in regulating 
PTEN phosphatase activity through ubiquitination 
which inhibits PTEN increasing AKT signalling 
(Lee et al., 2013). TRIM27 functions as an E3 
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ligase to ubiquitinate and inhibit PI3K-C2beta's 
kinase activity and negatively regulates CD4 T cells 
(Cai et al., 2011).  
TRIM27 also negatively regulates IgE receptor 
activation and downstream signalling by the same 
mechanism (Srivastava et al., 2012). TRIM27 
interacts with MAGE-L2 protein and ubiquitination 
of WASH K220 by MAGE-L2-TRIM27 is required 
for endosomal F-actin nucleation and retrograde 
transport (Hao et al., 2013). MRTF-B/TRIM27 
complex plays a role in the regulation of integrin b1 
expression via Rho and miR-124 in Leading Cells 
(LCs) among migrating cancer cell groups 
following loss of intracellular adhension (Kato et 
al., 2014). 
Homology 
H. sapiens, TRIM27 tripartite motif containing 27, 
513 aa. 
P. troglodytes (chimpanzee), TRIM27 tripartite 
motif containing 27, 513 aa (XP_001140726.2). 
M. mulatta, TRIM27 tripartite motif containing 27, 
513 aa (XP_001094465.2). 
C. lupus, TRIM27 tripartite motif containing 27, 
487 aa (XP_005642504.1). 
B. taurus, TRIM27 tripartite motif containing 27,  
 
 
513 aa (XP_001069267.1). 
M. musculus, Trim27 tripartite motif containing 27, 
513 aa (NP_033080.2). 
R. norvegicus, Trim27 tripartite motif containing 
27, 513 aa (NP_001128446.1). 
G. gallus, TRIM27 tripartite motif containing 27, 
505 aa (NP_001092824.1). 
With other RING finger/B box proteins. 
Mutations 
Germinal 
No germinal mutations described for TRIM27. 
Somatic 
TRIM27 have been identified in cancer tissues by 
large scale tumour genome sequencing at low 
frequency (see table above). COSMIC lists 26 
mutations from sequence analysis of 8960 cancers 
(mutation rate 0.29%).  
Mutation spectrum: one nonrecurrent, 8 
synonymous substitutions, one nonsense mutation, 
16 nonsynonymous missense substitutions mostly 
leading to conservative aminoacid changes. 
Evidence is not available at present whether these 
observed mutations affect function of TRIM27 or 
confer selective advantage to tumour cells 
(COSMIC). 
 
 
TRIM27 mutations identified in cancer. 
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Implicated in 
Thyroid papillary carcinoma (TPC) 
Disease 
A chromosomal translocation involving 
TRIM27/RFP is found in human thyroid papillary 
carcinomas.  
TPC is the most common cancer of the thyroid 
gland that usually begins as a small irregular solid 
lump (nodule) in the thyroid gland.  
Classical papillary carcinoma is characterised by 
the formation of papillae and a set of distinctive 
nuclear features (optically clear appearance, 
overlapping, pseudo-inclusions and nuclear 
grooves) (Rosai et al., 1992). 
Cytogenetics 
t(6;10)(p21.3;q11.2) 
Hybrid/Mutated gene 
TRIM27-RET; deltaTRIM27-RET. 
Abnormal protein 
Fusion of the N-terminus tripartite motif of 
TRIM27 with the truncated C-terminus tyrosine 
kinase domain of the c-ret proto-oncogene result in 
production of the ret transforming protein 
(Hasegawa et al., 1996; Saenko et al., 2003).  
The level of catalytic activity of the hybrid 
TRIM27-RET protein is higher than that of RET 
alone (Kato et al., 2000). 
Lung cancer 
Note 
TRIM27 mRNA or protein is highly expressed in 
human lung cancers.  
In a study that uses a cancer-profiling array 
containing tumour cRNA alongside cRNA from 
paired tissue, TRIM27 expression was found to be 
significantly increased in lung cancers versus 
normal tissue (Zoumpoulidou et al., 2012). 
TRIM27 expression is associated with poor 
prognosis of lung cancers with EGFR mutations 
suggesting that TRIM27 status might be associated 
with response to anticancer therapy in EGFR-
mutated lung cancers (Iwakoshi et al., 2012). 
Endometrial cancer 
Note 
Positive TRIM27 expression in human endometrial 
cancer cells is correlated with poor clinical outcome 
in patients (Tsukamoto et al., 2009). 
Immunohistochemical analysis of TRIM27 
expression in non-neoplastic endometrium samples 
as well as type I endometrial cancer in comparison 
to type II endometrial cancer has shown that 
TRIM27 positive expression was strongly 
correlated with serous carcinoma morphology 
(Tezel et al., 2012). 
Breast cancer 
Note 
Analysis of TRIM27 expression by Townson et al. 
revealed TRIM27 is expressed in breast cancer 
derived cell lines regardless of estrogen receptor 
(ER) status. However, it is not clear to what extend 
TRIM27 is involved in breast tumorigenesis 
(Townson et al., 2006). In a tissue microarray 
(TMA) study, TRIM27 protein expression was 
found in breast carcinomas but not in benign breast 
tissues. TRIM27 expression also correlates with 
ERBB2 protein expression and ERBB2 gene 
amplification, which is a marker for poor prognosis 
in breast cancer (Tezel et al., 2009). However, the 
biological significance of this correlation is not 
known. 
Ovarian cancer 
Note 
Immunohistochemical analysis of TRIM27 
expression in epithelial ovarian cancer shows that 
TRIM27 expression significantly correlates with 
chemoresistance in ovarian cancer patients. In 
addition, positive TRIM27 staining was increased 
in recurrent ovarian cancer, correlating with a poor 
outcome of the patients. TRIM27 protein 
expression was significantly higher in platinum-
resistant than in platinum-sensitive patients (Horio 
et al., 2012). Recombinant TRIM27 expression 
enhances chemoresistance of ovarian cancer cells to 
carboplatin and paclitaxel in culture and xenografts 
(Horio et al., 2012). 
Murine squamous carcinoma of the 
skin 
Note 
TRIM27 is highly expressed in chemically induced 
squamous cell carcinomas (SCC) in the mouse after 
exposure of the skin to the carcinogen 7, 12-
dimethylbenzanthracene (DMBA)/12-O-
tetradecanoylphorbol-13-acetate (TPA), as part of a 
two-step carcinogenesis model. Trim27 expression 
peaks in early mouse cancer development 
(Zoumpoulidou et al., 2012). Moreover, mice with 
TRIM27 deletion are resistant to development of 
chemically induced SSC (Zoumpoulidou et al., 
2012). 
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